According to the Kyoto Encyclopedia of Genes and Genomes (KEGG)[1], inotozumab ozogamicin (Besponsa®), developed by Pfizer, was also approved in Japan in January 2018.
Presumably, this was as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL), the same indication it was previously approved for in Europe.[2]
For further details regarding the first global approval of inotozumab ozogamicin in Europe please visit the First Global Approval report in Adis’ journal Drugs[3], which was based on the development milestones tracked in AdisInsight.[4]
Image credit: Ivelin Radkov / Fotolia
